GLP-1 Medications and Heart Health: New FDA-Approved Cardiovascular Benefits

The SELECT (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity) trial was one of the largest cardiovascular outcome studies ever conducted for a weight loss medication. Key findings from the trial: The trial enrolled over 17,600 adults aged 45+ with overweight or obesity and established cardiovascular disease (previous heart attack, stroke, or peripheral artery disease) but without diabetes. Participants receiving semaglutide 2.4mg weekly showed a 20% reduction in major adverse cardiovascular events (MACE) — a composite of cardiovascular death, non-fatal heart attack, and non-fatal stroke. The cardiovascular benefits appeared early, within the first few months of treatment, and persisted throughout the trial duration. Importantly, the heart benefits were observed independently of the amount of weight lost. Even patients who lost modest amounts of weight showed cardiovascular improvement, suggesting GLP-1 medications have direct cardioprotective effects beyond weight reduction.

Researchers have identified several mechanisms through which GLP-1 medications appear to benefit cardiovascular health: Anti-inflammatory effects: GLP-1 receptor agonists reduce systemic inflammation, including inflammatory markers like C-reactive protein (CRP) and interleukin-6 that drive atherosclerosis. Improved endothelial function: The medications help blood vessels dilate more effectively, improving blood flow and reducing arterial stiffness. Blood pressure reduction: Patients on semaglutide typically see systolic blood pressure drop by 3-6 mmHg, reducing strain on the cardiovascular system. Lipid improvements: GLP-1s improve cholesterol profiles, reducing triglycerides and increasing HDL cholesterol. Direct cardiac effects: GLP-1 receptors exist on heart muscle cells. Activation of these receptors appears to improve cardiac efficiency and reduce oxidative stress. Reduced ectopic fat: GLP-1 medications reduce fat deposits around the heart (epicardial fat) and in the liver, both of which are associated with cardiovascular risk.

The cardiovascular indication has significant implications for insurance access: The FDA-approved cardiovascular benefit gives insurers a compelling reason to cover GLP-1 medications beyond weight loss. Many insurers that previously denied coverage for "cosmetic" weight loss now approve coverage when the prescription includes cardiovascular risk reduction. Medicare coverage has been particularly impacted. While Medicare historically excluded weight loss drugs, cardiovascular medications have always been covered. The dual indication gives providers a pathway to prescribe Wegovy with cardiovascular justification. Prior authorization success rates have improved significantly since the cardiovascular approval. Providers report that citing cardiovascular risk reduction alongside obesity treatment increases approval rates. However, some insurers still require documentation of established cardiovascular disease for the cardiovascular indication. Discuss with your provider how to frame your prescription for the best chance of coverage.

Eli Lilly's SURPASS-CVOT trial is evaluating tirzepatide's cardiovascular effects. Preliminary data suggests similar cardioprotective benefits: The trial is expected to report full results in 2026, potentially leading to a cardiovascular indication for Zepbound as well. Given tirzepatide's greater weight loss efficacy (up to 25%+ body weight), researchers are optimistic about its cardiovascular potential. If approved, a tirzepatide cardiovascular indication would give patients and providers another option and further expand insurance coverage pathways.

Based on current evidence and FDA approvals, GLP-1 medications for cardiovascular benefit are most appropriate for: